Lincoln Pharma

Lincoln Pharma Increases Promoter Group Holding by 4.9% during FY 20-21 to 37.25%.

ICRA in its recent report has upgraded rating on long-term bank facilities to ICRA A and short-term facilities to ICRA A1 backed by steady growth in margins and improvement in risk profile